Last reviewed · How we verify
Gemcitabine plus Capecitabine
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Capecitabine is a prodrug of 5-fluorouracil that inhibits thymidylate synthase.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while Capecitabine is a prodrug of 5-fluorouracil that inhibits thymidylate synthase. Used for Breast cancer, Pancreatic cancer, Non-small cell lung cancer.
At a glance
| Generic name | Gemcitabine plus Capecitabine |
|---|---|
| Also known as | Neoadjuvant chemotherapy, GemCap |
| Sponsor | Asan Medical Center |
| Drug class | Nucleoside analog and thymidylate synthase inhibitor |
| Target | DNA polymerase and thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gemcitabine and Capecitabine work synergistically to induce apoptosis in cancer cells by disrupting DNA replication and repair.
Approved indications
- Breast cancer
- Pancreatic cancer
- Non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (PHASE2, PHASE3)
- Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (NA)
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine plus Capecitabine CI brief — competitive landscape report
- Gemcitabine plus Capecitabine updates RSS · CI watch RSS
- Asan Medical Center portfolio CI